Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 3/20 | 0.58 |
| ▸ | ESR1 | P03372 | 5/20 | 0.49 |
| ▸ | ESR2 | Q92731 | 5/20 | 0.49 |
| ▸ | LMNA | P02545 | 3/20 | 0.46 |
| ▸ | GAA | P10253 | 2/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.44 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.44 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.44 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.44 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.44 |
| ▸ | GAPDH | P04406 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.43 |
| ▸ | CA12 | O43570 | 2/20 | 0.43 |
| ▸ | CA9 | Q16790 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | GLA | P06280 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7636676 | 0.93 | CA2 (0.51) | CA2ESR1ESR2LMNAGAA | |
| SCHEMBL7641278 | 0.93 | ESR1 (0.60) | CA2ESR1ESR2HDAC6HDAC3 | |
| SCHEMBL7645110 | 0.93 | CA2 (0.54) | CA2ESR1ESR2LMNAGAA | |
| SCHEMBL7642201 | 0.91 | CA2 (0.56) | CA2ESR1ESR2LMNAGAA | |
| SCHEMBL21470083 | 0.91 | CA2 (0.53) | CA2ESR1ESR2LMNAGAA | |
| SCHEMBL7642766 | 0.90 | ESR1 (0.65) | CA2ESR1ESR2LMNAGAA | |
| SCHEMBL7639250 | 0.87 | APP (0.58) | CA2LMNAGAAHSD17B10HDAC6 | |
| SCHEMBL20275901 | 0.86 | CA2 (0.47) | CA2ESR1ESR2HSD17B10HDAC6 | |
| SCHEMBL7645063 | 0.85 | CA2 (0.47) | CA2ESR1ESR2HSD17B10HDAC6 | |
| SCHEMBL7775891 | 0.84 | CA2 (0.61) | CA2ESR1ESR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2005003116-A9 | PROCESS FOR PREPARING RALOXIFENE HYDROCHLORIDE | ERREGIERRE SPA (IT) | 2008-09-25 | — | — | WO | claimed |
| EP-1641773-B1 | PROCESS FOR PREPARING RALOXIFENE HYDROCHLORIDE | ERREGIERRE SPA (IT) | 2008-07-23 | — | — | EP | claimed |
| US-20070100147-A1 | Process for preparing raloxifene hydrochloride | ERREGIERRE S.P.A (IT) | 2007-05-03 | — | — | US | claimed |
| EP-1641773-A1 | PROCESS FOR PREPARING RALOXIFENE HYDROCHLORIDE | ERREGIERRE S.p.A. (IT) | 2006-04-05 | — | — | EP | claimed |
| WO-2005003116-A1 | PROCESS FOR PREPARING RALOXIFENE HYDROCHLORIDE | ERREGIERRE S.P.A. (IT) | 2005-01-13 | — | — | WO | claimed |
| US-6395769-B1 | ACTIVATION ESTROGEN; THERAPY FOR OSTEOPOROSIS, ANTILIPEMIC AGENTS | ELI LILLY AND COMPANY | 2002-05-28 | — | — | US | claimed |
| US-6096781-A | 2-PHENYL-1-BENZOTHIOPHENE DERIVATIVES ARE USEFUL FOR TREATMENT OF OSTEOPOROSIS AND HYPERLIPEMIA | ELI LILLY AND COMPANY (US) | 2000-08-01 | — | — | US | claimed |
| EP-0920862-A1 | 2-Arylbenzo b thiophenes useful for the treatment of estrogen deprivation syndrome | ELI LILLY AND COMPANY (US) | 1999-06-09 | — | — | EP | claimed |
| WO-2011132194-A1 | PROCESS FOR THE PREPARATION OF RALOXIFENE HYDROCHLORIDE | HETERO RESEARCH FOUNDATION (IN) | 2011-10-27 | — | — | WO | disclosed |
| WO-2005003116-A9 | PROCESS FOR PREPARING RALOXIFENE HYDROCHLORIDE | ERREGIERRE SPA (IT) | 2008-09-25 | — | — | WO | disclosed |
| WO-2005003116-A9 | PROCESS FOR PREPARING RALOXIFENE HYDROCHLORIDE | ERREGIERRE SPA (IT) | 2008-09-25 | — | — | WO | disclosed |
| EP-1641773-B1 | PROCESS FOR PREPARING RALOXIFENE HYDROCHLORIDE | ERREGIERRE SPA (IT) | 2008-07-23 | — | — | EP | disclosed |
| EP-1641773-B1 | PROCESS FOR PREPARING RALOXIFENE HYDROCHLORIDE | ERREGIERRE SPA (IT) | 2008-07-23 | — | — | EP | disclosed |
| US-20070100147-A1 | Process for preparing raloxifene hydrochloride | ERREGIERRE S.P.A (IT) | 2007-05-03 | — | — | US | disclosed |
| EP-0693488-A1 | An improved process for preparing 3-(4-aminoethoxy-benzoyl)benzo beta -thiophenes | ELI LILLY AND COMPANY (US) | 1996-01-24 | — | — | EP | disclosed |
| EP-0062504-B1 | PROCESS FOR PREPARING 3-(4-AMINOETHOXYBENZOYL)BENZO(B)THIOPHENES | ELI LILLY AND COMPANY (US) | 1986-01-02 | — | — | EP | disclosed |
| US-4418068-A | Antiestrogenic and antiandrugenic benzothiophenes | ELI LILLY AND COMPANY (US) | 1983-11-29 | — | — | US | disclosed |
| US-4358593-A | BY ACYLATION OF PROTECTED 6-HYDROXY,2-(4-HYDROXYPHENYL) BENZO (B)THIOPHENE USING A FRIEDEL CRAFTS CATALYSTS; HYDROLYSIS | ELI LILLY AND COMPANY (US) | 1982-11-09 | — | — | US | disclosed |
| EP-0062503-A1 | Benzothiophene compounds and process for preparing them | ELI LILLY AND COMPANY (US) | 1982-10-13 | — | — | EP | disclosed |
| EP-0062504-A1 | Process for preparing 3-(4-aminoethoxybenzoyl)benzo(b)thiophenes | ELI LILLY AND COMPANY (US) | 1982-10-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070100147-A1 | Process for preparing raloxifene hydrochloride | KAT2A, ADH1A, KAT2B | CA2 158/4885ESR1 78/4885ESR2 69/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.